Advisory Board & Venture Partners
Dr. Thomas Hecht
Past and present Chairman or Director at several biopharmaceutical companies, including ESBATech, Cytos, Affimed, Cellmedica, Suppremol, Humabs, and Vaximm; senior veteran from Amgen Europe (Clinical, Med affairs & Marketing)
Prof. Dr. Roger Nitsch
University of Zurich, key opinion leader in neurodegenerative diseases; directs the Institute for Regenerative Medicine; Co-founder and Chairman of Neurimmune, developer of aducanumab, now in partnership with Biogen (Alzheimer’s disease).
Dr. Mathieu Simon
Former EVP, COO and board director of Cellectis, a premier CAR T-cell and DNA editing company, NASDAQ listed (CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.
Prof. Dr. Dr. Klaus Strein
Board Director at BB Biotech AG; Co-founder, Chairman and CEO of Engmab, sold to Celgene in a landmark exit in 2016; previously at Roche Head of small & large molecule research and prior to that Head of Pharma R&D at Boehringer Mannheim.
Portfolio Manager at BB Biotech AG in New York since 2006, prior healthcare equity analyst positions with Stanford, Sterling, and Adam Harkness & Hill. Dallas holds an MBA and a BS in Microbiology.
Previously CEO of Nordic Nanovector, a Norwegian oncology/hematology company, he IPOed in 2015 at the Oslo stock exchange. Previously at Eli Lilly and in senior management positions with Amgen and Onyx in regional and commercial leadership roles.